Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Managing type 1 diabetes in children often means balancing insulin injections, meals, school activities, and unpredictable blood sugar changes. Could inhaled insulin make mealtime treatment easier without sacrificing glucose control? Recent research on inhaled insulin for children with type 1 diabetes offers promising findings, alongside important limitations. The INHALE clinical program evaluated Technosphere insulin, marketed as Afrezza, as an alternative to injected mealtime insulin. Although the results highlight greater treatment satisfaction and potential benefits for postmeal glucose management, careful dosing and lung safety monitoring remain essential.
Table of Contents
- How Inhaled Insulin Works for Children With Type 1 Diabetes
- What the INHALE-1 Trial Revealed About Pediatric Diabetes Care
- Safety, Dosing, and Pulmonary Considerations
- Which Children With Type 1 Diabetes May Benefit?
- Conclusion
- Frequently Asked Questions
How Inhaled Insulin Works for Children With Type 1 Diabetes
Traditional type 1 diabetes treatment requires insulin to replace the hormone the pancreas can no longer produce. Typically, children receive long-acting basal insulin and rapid-acting insulin with meals, or use an insulin pump.
However, repeated injections can create physical discomfort and emotional stress, particularly among younger patients.
Technosphere insulin offers another method of delivering mealtime insulin. Instead of injecting insulin beneath the skin, patients inhale a dry powder that passes through the lungs into the bloodstream.
Because absorption occurs rapidly, the medication begins working sooner than many injected mealtime insulin formulations. Its shorter duration may also help limit insulin activity after meal-related glucose levels have declined.
Consequently, inhaled insulin may offer greater flexibility around meals.
Afrezza received expanded FDA approval in May 2026 for patients aged six years and older with diabetes. Importantly, the medication replaces mealtime insulin rather than the basal insulin required for type 1 diabetes.
Furthermore, its use requires specific inhalation techniques, appropriate dosing, and continued glucose monitoring.
For families interested in reducing injections, these features make inhaled insulin worth discussing with their diabetes care team.
What the INHALE-1 Trial Revealed About Pediatric Diabetes Care
The INHALE-1 randomized clinical trial evaluated 230 children and adolescents aged 4 to 17 years, including 225 participants with type 1 diabetes.
Researchers compared inhaled Technosphere insulin with injected rapid-acting insulin analogs over 26 weeks. Both treatment groups continued basal insulin and continuous glucose monitoring.
The primary goal was to determine whether inhaled insulin provided HbA1c outcomes sufficiently close to those achieved with injections.
At baseline, mean HbA1c was approximately 8.2% in both groups. After 26 weeks, HbA1c reached 8.41% with inhaled insulin and 8.21% with injected insulin.
Importantly, the primary analysis did not establish noninferiority, meaning researchers could not confirm that inhaled insulin performed within the study's predefined acceptable difference.
However, a sensitivity analysis excluding one participant who did not follow the study protocol met the noninferiority standard.
Time in range also showed no statistically significant difference between treatment groups.
Despite these mixed glucose outcomes, participants using inhaled insulin reported significantly greater treatment satisfaction and experienced less weight gain.
Postmeal Glucose Control and Longer-Term Findings
Additional research from the INHALE program examined glucose changes following meals.
A meal-challenge analysis found that children receiving Technosphere insulin experienced postmeal glucose patterns similar to adults using the same treatment.
The pediatric group also demonstrated smaller glucose excursions than a separate adult cohort using injected rapid-acting insulin. However, this comparison should not be interpreted as proof of superior pediatric outcomes.
Meanwhile, findings from the 52-week INHALE-1 extension study raised another consideration.
Average HbA1c increased during extended inhaled insulin treatment, reinforcing the need for ongoing dose adjustment and glucose monitoring.
Together, these findings suggest that reducing injections may improve the treatment experience without guaranteeing better long-term glycemic control.
Safety, Dosing, and Pulmonary Considerations
Although inhaled insulin eliminates some injections, it introduces safety requirements that differ from conventional insulin therapy.
Most importantly, Afrezza carries an FDA boxed warning concerning acute bronchospasm in patients with chronic lung disease.
Therefore, children with asthma or other chronic lung conditions are not appropriate candidates.
Before treatment begins, clinicians must evaluate respiratory health and perform spirometry to measure lung function.
According to the Afrezza prescribing information, pulmonary function should be reassessed after six months and annually thereafter.
Additionally, cough and throat irritation are recognized adverse effects.
In INHALE-1, researchers found no significant difference in lung function changes between inhaled and injected insulin groups over 26 weeks. Nevertheless, these findings do not eliminate the need for longer-term surveillance.
Dosing presents another challenge. Inhaled insulin units are not directly interchangeable with injected insulin units, and available cartridge strengths may limit fine dose adjustments.
Furthermore, its rapid action can require additional monitoring and carefully planned correction doses.
For example, delayed glucose increases after meals may require individualized management rather than simply repeating the initial dose.
Hypoglycemia remains possible, while insufficient insulin delivery can increase hyperglycemia and diabetic ketoacidosis risk.
Therefore, safe treatment depends on education, consistent monitoring, and close clinical follow-up.
Which Children With Type 1 Diabetes May Benefit?
Choosing the right patients is essential when considering inhaled insulin for children and adolescents with type 1 diabetes.
Children who experience significant injection distress may benefit from an alternative method of mealtime insulin delivery.
Similarly, adolescents seeking greater independence may appreciate an inhaler-based option.
However, treatment decisions should account for age, respiratory health, insulin requirements, and the ability to use the device correctly.
Exploratory findings from the INHALE program suggest that certain patient subgroups may achieve more favorable outcomes. Nevertheless, these analyses require cautious interpretation and should not replace individualized clinical assessment.
Current US labeling permits Afrezza use beginning at age six, although the clinical trial enrolled some younger participants.
Clinicians should also assess caregiver involvement, carbohydrate counting skills, and the family's capacity to respond to changing glucose levels.
As discussed in Diabetes in Control's coverage of pediatric diabetes technology, technology can support diabetes management, but practical barriers remain important.
Ultimately, shared decision-making should weigh the convenience of fewer injections against pulmonary monitoring, dosing complexity, and individual glucose outcomes.
Conclusion
Pediatric inhaled insulin represents a meaningful expansion of mealtime treatment options for type 1 diabetes.
The INHALE program demonstrated greater treatment satisfaction and reassuring short-term pulmonary findings. However, its primary trial did not establish HbA1c noninferiority, and longer-term results highlight the importance of careful follow-up.
For appropriately selected children, Afrezza may reduce the burden of mealtime injections. Nevertheless, it cannot replace basal insulin, glucose monitoring, or individualized diabetes education.
The most effective approach remains one that balances treatment convenience, safety, and sustained glucose control.
Frequently Asked Questions
1. Is inhaled insulin FDA-approved for children with type 1 diabetes?
Yes. As of May 2026, Afrezza is FDA-approved for adults and children aged six years and older with diabetes, including type 1 diabetes.
2. Can children completely replace insulin injections with inhaled insulin?
No. Inhaled insulin provides mealtime coverage. Children with type 1 diabetes still require basal insulin through an appropriate delivery method.
3. Does pediatric inhaled insulin improve blood sugar control after meals?
Research suggests favorable postmeal glucose patterns. However, INHALE-1 did not demonstrate superior overall glucose control or meet its primary HbA1c noninferiority objective.
4. Is inhaled insulin safe for children with asthma?
No. Afrezza is contraindicated in patients with chronic lung disease, including asthma, because of the risk of acute bronchospasm.
5. What monitoring is needed for children using inhaled insulin?
Patients require regular glucose monitoring, individualized dose adjustments, and lung function testing before treatment, after six months, and annually.
Medical Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.